MISSION
Our mission is to develop novel technologies that will enable greater access of cell and gene therapies globally. We focus on R&D in next-generation point-of-care devices that will enable rapid, safe and affordable cell and gene therapies.
Current methods are:
Expensive
Labor and capital intensive
Labor and capital intensive
Produce cells that contain residual chemicals that have to be removed in post-processing and that increase the cost and time and reduce the quality of the cells.
Focus areas:
Stem cell (MSC) purification for autologous transplantation T-cell purification for CAR-T therapy Single-patient to industrial scale
As seen on
-p-2000.jpeg)
Fast, reliable and efficient. ARD have solved our R&D problem, that was lingering for years, in two months.
Joshua Cohen
Computerize
Expert analysis of the market and customer needs. We were able to create a tailored solution that our customers actually wanted and were willing to pay for!
CEO.
U-topia
Trusted Partners
